



The “good” medicine for cats and dogs

Friulchem and its patented Fc-Cubes technology produce highly palatable chewable tablets to facilitate the administration of veterinary medicines

A

nimals: what a passion. But not only. This could be the slogan for Friulchem, an innovative chemical and pharmaceutical firm with solid roots in Italy and production facilities in Vivaio (Pordenone) and administrative headquarters in Milan.

Active since 1996 (50 employees, €34.3 million in revenue, one share owned by the regional financial company Friulia, listed since 2019 on the Euronext Growth stock exchange), Friulchem is today one of the foremost Italian actors in the field of pharmaceutical production for third parties. The Friulian-Lombard company has set itself the aim of focusing on the development of delivery systems for veterinary medicines and supplements. It is one of a kind on the market due to its research and development activities, through which it has established relationships with the industry's leading multinational corporations.

The research laboratory is staffed by seasoned professionals and equipped with cutting-edge technology to support method development, product validation and ongoing product quality. Fc-Cubes, a patented Italian technology exclusive to the veterinary industry,

are among the solutions developed by Friulchem. These chewable tablets are extremely palatable for domestic pets such as cats and dogs.

“Due to its innovative solutions in the fields of pharmaceuticals, supplements and additives, our company is a leader in the veterinary market and has the goal of enhancing Italian-made products”, explains CEO Disma Giovanni Mazzola. Through its subsidiary FC France, in 2022 Friulchem also acquired a 70% stake in Arcanatura, a French company specialising in the treatment of illnesses affecting pets such as cats and dogs. This transaction will enable substantial growth on the French veterinary market. “With the financial strengthening of our French subsidiary FC France and the subsequent acquisition of Arcanatura”, explains Mazzola, “we are continuing our growth and development strategy, confirming our desire to play an ever-increasing role on the veterinary market in France and throughout Europe. Friulchem is an innovative company that provides one-of-a-kind solutions and technologies to satisfy the market's growing demands. The proprietary

Fc-Cubes technology is definitely a hallmark of our company and we are proud to be able to implement its production and distribution”.

Friulchem's Board of Directors recently approved the draft budget for 2023 and the final report as at 31 December 2022, with results showing a good turnover trend for both Friulchem Spa and the Group as a whole, as well as an increase in sales thanks to the introduction of new products for new customers.

“2022 was a satisfying year for Friulchem and the results achieved are a confirmation of the validity and solidity of the company's business model. We have shown that we are capable of seizing the opportunities in the market and the positive trend allows us to be optimistic about 2023”, Mazzola comments.

Friulchem will continue to place research and development at the centre of its operations, with a focus on the uniqueness of its solutions and production, as well as the consolidation of its sales activities, in order to confirm its position at the national and international level, ensuring high quality, production, and environmental standards. A source of strength will be the synergy with FC France, a company that is acquiring significant competitive advantages





► 24 April 2023

and increasing its production and presence on the French market.

Alessandro Rinaldi
© ALL RIGHTS RESERVED



Disma Giovanni Mazzola
We are an innovative company offering distinctive solutions for a very demanding market

